Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Update

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the recipient of a large decrease in short interest in February. As of February 15th, there was short interest totalling 57,500 shares, a decrease of 31.1% from the January 31st total of 83,500 shares. Approximately 2.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 636,200 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Aegis reiterated a “buy” rating and issued a $15.00 price target on shares of Sunshine Biopharma in a research report on Thursday, December 5th.

Sunshine Biopharma Trading Down 7.0 %

NASDAQ:SBFM traded down $0.16 during midday trading on Tuesday, hitting $2.15. 50,994 shares of the company traded hands, compared to its average volume of 279,006. The firm has a market capitalization of $2.63 million, a P/E ratio of -0.01 and a beta of 1.33. The firm’s fifty day moving average is $2.76 and its 200-day moving average is $2.83. Sunshine Biopharma has a 12-month low of $2.05 and a 12-month high of $285.00.

Institutional Investors Weigh In On Sunshine Biopharma

A hedge fund recently bought a new stake in Sunshine Biopharma stock. Connective Capital Management LLC bought a new stake in shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,345 shares of the company’s stock, valued at approximately $34,000. Connective Capital Management LLC owned about 0.93% of Sunshine Biopharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 41.98% of the company’s stock.

About Sunshine Biopharma

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.